Teon Therapeutics

Teon Therapeutics, Inc specializes in creating oral cancer therapies aimed at restoring immune function against tumors. The company was founded by Elfatih Elzein, Lina Yao, and Peter Fan, with its headquarters in Redwood City, US.Teon Therapeutics specializes in developing innovative, once-daily, oral cancer medications aimed at restoring anti-tumor immunity. The company’s core product offerings focus on targeted therapies that exploit untapped metabolic signaling pathways, particularly emphasizing the potential benefits of G-protein coupled receptor (GPCR) signaling. These therapies seek to address difficult-to-treat cancers by reversing immune cell suppression and halting tumor growth. Teon’s pipeline includes first- and best-in-class candidates designed to improve patient outcomes, enabling them to spend more time with loved ones rather than undergoing lengthy infusions.Teon Therapeutics generates revenue through a model centered on the development and commercialization of its proprietary cancer therapies. The company engages in partnerships with healthcare institutions and pharmaceutical companies to facilitate the distribution of its GPCR-directed therapies. These partnerships allow for a streamlined approach in bringing novel treatments to market while leveraging the expertise of established players in oncology. Transactions typically involve agreements for the supply of these therapies to oncology practices and hospitals, which then administer the medications to patients. Revenue is driven through direct sales in clinical settings, where healthcare providers procure the therapies to be offered as part of their treatment regimens. The company aims to expand its reach into new markets, particularly focusing on oncology practices in both the United States and Europe.

1. Series A

   Feb 22, 2021

   Amount

   $30M

   Investors

   Locked